Forte Biosciences disclosed its full‑year 2025 financial results, reporting a net loss of $69.4 million, a significant increase from the $35.5 million loss recorded in 2024. The widening loss reflects the company’s intensified investment in the development of its anti‑CD122 antibody, FB102, across celiac disease, vitiligo, and alopecia areata.
Research and development expenses climbed to $58.2 million in 2025, up from $21.2 million in 2024, underscoring the company’s focus on advancing FB102 into Phase 2 and Phase 1b trials. The spike in R&D spending is a deliberate strategy to accelerate clinical milestones that could unlock multi‑billion‑dollar markets.
Forte’s cash and cash equivalents stood at $77.0 million at year‑end, providing a solid runway to support ongoing trials and potential future financing needs. The cash position, combined with the company’s equity‑funded capital structure, positions Forte to sustain its clinical program through the critical 2026 readouts.
Management highlighted that key data from the Phase 2 celiac disease study and Phase 1b studies in vitiligo and alopecia areata are expected in 2026. “The topline results from our phase 2 celiac disease study is expected in 2026,” CEO Paul Wagner said, emphasizing the importance of these data for future partnership or acquisition discussions.
While the company’s earnings remain negative, the broader context shows a company investing heavily in a single, potentially transformative asset. The increased R&D spend and robust cash position suggest management’s confidence in FB102’s clinical trajectory, even as the company continues to post losses in the absence of approved products.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.